GT Diagnostics

What GT Diagnostics does

GT Diagnostics is a privately held health technology company that develops digital tools for the diagnosis and monitoring of dementia, operating through Genting TauRx Diagnostic Centre Sdn Bhd (Malaysia, founded 2012) and its wholly owned UK subsidiary GT Diagnostics (UK) Limited (established 2020, headquartered in Aberdeen). The company is a joint venture between Malaysian conglomerate Genting Berhad and TauRx Pharmaceuticals Ltd Group, and its portfolio spans home-based cognitive wellbeing apps, professional tablet-based clinical assessments, and EEG-based biomarker analysis. No external funding rounds have been disclosed.

The product lineup includes HiPAL, a freemium consumer wellbeing app for self-monitoring cognitive health (0-100 score adjusted for age and sex, monthly tracking, multi-user device sharing) launched in July 2023; HiPAL Pro, an FDA 510(k) Exempt, self-administered psychometric tool running on tablet for clinicians (launched August 2023 in the USA); PsyCoXx, a computer adaptive testing tool under development; and SigNeXx, an EEG-based brain connectivity analysis tool under development using patented network analysis technology. All assessments are designed to be language-agnostic and image-based to reduce cultural and literacy barriers, with proprietary scoring algorithms that generate outputs mapped to established scales such as MMSE.

GT Diagnostics generates revenue through three streams: freemium consumer subscriptions on the HiPAL app (iOS and Android), enterprise/B2B sales of HiPAL Pro to clinicians, primary care facilities, and expert dementia centers, and platform licensing and distribution partnerships with care service providers. The company pursues a hybrid go-to-market combining product-led consumer acquisition, direct enterprise field sales, channel partnerships, and event-driven engagement at major dementia and Alzheimer's conferences. It holds ISO 13485:2016 certification (2024) and Malaysian GDPMD conformance, and operates in the USA, UK, Malaysia, and parts of Europe, with a UAE proof-of-concept study in 2025 signaling Middle East expansion intent.

Name

GT Diagnostics

Legal name

Genting TauRx Diagnostic Centre Sdn. Bhd.

Website

https://gtdiag.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

GT Diagnostics develops digital cognitive assessment tools for dementia detection and monitoring, serving consumers via the HiPAL app and clinicians via the FDA-listed HiPAL Pro tablet tool, with two further products (PsyCoXx, SigNeXx) under development.

Ownership category

akta.pro rank

Product category

Digital Cognitive Diagnostics / Dementia Assessment Software

NAICS

Services for the Elderly and Persons with Disabilities (62412)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)

akta.pro secondary industries

Geriatric, Frailty & Fall-Prevention Remote Monitoring (HLALAFAI), Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM), Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

Keywords

• Cognitive assessment software
• Dementia diagnostic tools
• Digital health platforms
• Medical device software
• Neuropsychological testing

Headquarters

HQ city

Aberdeen

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Consumer App Subscriptions (HiPAL): Freemium model with free tier providing single assessment and premium subscription for unlimited assessments, progress tracking, and device sharing. Available on iOS and Android.
2. Professional Diagnostic Tools: Clinical tools (HiPAL Pro) distributed to healthcare facilities including primary care waiting rooms and expert centers. Revenue from clinical facility licenses and enterprise agreements.
3. B2B Platform Licensing: Integration of diagnostic tools through service providers including care systems, residential facilities, and dementia centers. Distribution and integration partnerships.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

GT Diagnostics develops a portfolio of digital cognitive assessment and dementia diagnostic tools, ranging from a consumer wellbeing app (HiPAL) for self-monitoring cognitive health at home to professional clinical tools (HiPAL Pro, PsyCoXx, SigNeXx) used by clinicians in primary care and specialist dementia centers. The tools use image-based, language-agnostic assessments, proprietary scoring algorithms, computer adaptive testing, and EEG-based biomarker analysis to enable earlier and more accessible detection of cognitive impairment.

Product overview

GT Diagnostics develops a portfolio of dementia detection applications and diagnostic tools spanning from home-based wellbeing apps to professional clinical tools. The product lineup includes HiPAL (consumer wellbeing app for home cognitive monitoring), HiPAL Pro (FDA-listed professional tablet-based assessment tool for clinicians), PsyCoXx (computer adaptive testing tool for clinical assessment under development), and SigNeXx (EEG-based brain connectivity analysis tool under development). These tools are designed to be non-invasive, language-agnostic, and integrated into existing diagnostic pathways across primary care facilities and expert centres.

Differentiator

Problem solved

Functional benefit

Brands

• HiPAL: Interactive cognitive wellbeing app designed to help users monitor memory, attention, and processing speed through brief assessments. Available for home use.
• HiPAL Pro
• PsyCoXx
• SigNeXx

Products and services

• HiPAL Interactive cognitive wellbeing app that enables individuals to monitor memory performance, attention, and processing speed through brief assessments at home. The app provides a single simplified score (0-100) adjusted for age and sex, with monthly tracking support. Available on iOS and Android via App Store and Google Play with a freemium model.
• HiPAL Pro Self-administered professional tool running on tablet that supports clinicians in evaluating objective and subjective memory and mental processing speed. FDA-listed computerized cognitive assessment aid designed to assist in diagnosis and monitoring of dementia, particularly Alzheimer's disease. Distributed to primary care waiting rooms and expert dementia centers in the USA via direct enterprise sales.
• PsyCoXx Computer adaptive testing tool for clinicians to use in assessment of patients with suspected or confirmed dementia, including Alzheimer's disease. Provides a full 3D view of a patient's cognitive profile using only informative questions at the appropriate difficulty level. Currently under development.
• SigNeXx Non-invasive, advanced electroencephalography (EEG)-based analysis tool using standard EEG acquisition devices that provides an objective measure of brain connectivity. Delivers quantitative evaluation of standard EEG recordings to aid in diagnosis and monitoring of patients with dementia, particularly Alzheimer's Disease. Currently under development, with patented network analysis technology as its technical foundation.

Quantifiable outcome

• 75% of people with dementia globally are undiagnosed (41 million people)
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered founding, major, core and supporting.

• Genting BerhadfoundingStrategic or Co-development PartnerMalaysian conglomerate and founding partner of GT Diagnostics. Genting Berhad collaborated with TauRx Pharmaceuticals to establish Genting TauRx Diagnostic Centre Sdn Bhd in 2012 with the vision to change the diagnostic landscape in dementia.
• TauRx Pharmaceuticals LtdfoundingStrategic or Co-development PartnerTauRx Pharmaceuticals Ltd Group is the co-founding partner with Genting Berhad. The collaboration created GT Diagnostics to develop diagnostic tools that complement TauRx's Alzheimer's disease treatments.
• Alzheimer's AssociationmajorGTM or Marketing PartnerGT Diagnostics showcased and launched HiPAL at the Alzheimer's Association International Conference 2023 in Amsterdam. Strategic venue for product launch and healthcare professional outreach.
• TauRx Therapeutics LtdcoreStrategic or Co-development PartnerTauRx Therapeutics, a subsidiary focused on tau-based Alzheimer's treatments, collaborates with GT Diagnostics on symposium presentations at Alzheimer Europe Conference discussing late-stage clinical trial conduct and diagnostic tools.
• Guardian Media GroupsupportingGTM or Marketing PartnerGT Diagnostics supported the Understanding Dementia campaign launched in The Guardian, featuring company executives in editorial content about dementia research and emerging developments.
• The ScotsmansupportingGTM or Marketing PartnerFeatured article partnership with The Scotsman featuring GT Diagnostics CEO alongside TauRx CEO on revolutionary Alzheimer's treatment developments and company collaboration.
• Alzheimer's Research UK (ARUK)supportingGTM or Marketing PartnerGT Diagnostics was an exhibitor at the ARUK conference, the largest dementia research conference in the UK, showcasing products in development to healthcare professionals and researchers.
• Alzheimer Disease International (ADI)supportingGTM or Marketing PartnerGT Diagnostics participated in ADI Report 2021 Webinar series on Innovations in diagnosis and diagnostics, contributing presentations on at-home diagnostic tools and monitoring importance.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Emerging players

• Cerveau Technologies: Provider of tau PET imaging biomarkers to pharmaceutical and academic researchers for Alzheimer's and related dementia research. Emerging peer: overlaps with SigNeXx's tau-relevant biomarker strategy and shares GT Diagnostics' pharma-trial-endpoint go-to-market, but via imaging rather than EEG.
• Novoic: AI-driven speech biomarker company developing digital cognitive assessments for dementia and other neurological conditions. Emerging peer: shares the AI/digital-cognitive-assessment approach and pharma-sponsored validation pathway, but uses voice biomarkers rather than visual/tablet tests.

Broad incumbents

• Roche: Diversified diagnostics and pharma giant with Elecsys Alzheimer's CSF/blood assays, digital health initiatives, and broad clinical channels. Broad incumbent: represents both the scale incumbent in Alzheimer's diagnostics and a potential strategic buyer or channel partner for validated digital cognitive endpoints.
• Biogen: Large biopharmaceutical company with Alzheimer's franchise (e.g., Aduhelm/Leqembi partnerships) and growing emphasis on diagnostics and early detection. Broad incumbent: defines the commercial demand profile for dementia diagnostics, and a potential partner/competitor for companion-diagnostic positioning.

Direct peers

• C2N Diagnostics: Diagnostics company commercializing blood-based biomarkers (PrecivityAD) for Alzheimer's detection, bridging primary care and specialist workups. Direct peer: targets the same '75% undiagnosed' opportunity with complementary biomarker-based diagnostic outputs (blood vs. digital cognitive).
• Neurotrack: Digital health company developing cognitive assessments for early detection of Alzheimer's and memory impairment, including consumer and clinician-facing tools. Direct peer: shares GT Diagnostics' focus on consumer/professional screening along the continuum of cognitive health.
• Altoida: Digital cognitive assessment company using augmented reality and AI on smartphones/tablets to detect mild cognitive impairment and Alzheimer's disease. Direct peer: employs similar device-based, AI-driven, non-invasive cognitive assessment for early dementia identification.
• Cambridge Cognition: Developer of CANTAB cognitive assessment tools used widely in CNS clinical trials and clinical practice. Direct peer: competes directly with HiPAL Pro/PsyCoXx as a validated, digital, tablet-based cognitive battery for dementia research, pharma sponsors, and clinical settings.
• Linus Health: Digital cognitive assessment platform combining tablet-based tests with AI and voice biomarkers for early dementia detection. Direct peer: targets the same primary-care and specialty clinician segments with self-administered, non-invasive cognitive screening for early Alzheimer's detection.
• Cogstate: Public digital cognitive assessment company offering computerized tests for clinical trials, healthcare, and research. Direct peer: shares GT Diagnostics' core focus on validated, computerized cognitive endpoints for dementia/Alzheimer's trials and clinical use, with overlapping target customers (pharma sponsors, clinicians).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GtDiagnostics
• YouTubeyoutube.com/channel/UCDj7QqvX54SHj1eqcEqLugA
• Facebookfacebook.com/gtdiagnostics
• LinkedInlinkedin.com/company/gt-diagnostics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GT Diagnostics